ClinicalTrials.gg
CompletedNCT05497843Updated Apr 3, 2025

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

A Phase 2 interventional study of Chiauranib in Soft Tissue Sarcoma, sponsored by Chipscreen Biosciences, Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Chipscreen Biosciences, Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 133 studies in Sarcoma with a site in China — 68 open to participants now, 75 under way, 1 of them phase 3. Sarcoma · China.

Enrollment
65th of 122
40 · median 45
Started
2022
with 11 others
Phase 2
67 of 133
32 open now
Registered
66th of 133
by date

Among the 133 studies in Sarcoma with a site in China, this one is the 65th largest by enrollment of the 122 interventional ones that give a count, is one of 12 that started in 2022, is one of 67 in phase 2, and was the 66th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

68 of the 133 studies in Sarcoma with a site in China are open now. Recruiting first, the newest first:

63 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Sarcoma with a site in China, or all of them as a file.
02

Study summary

This is a Phase 2, single-arm, open-label study in patients with advanced or unresectable soft tissue sarcoma.

Read the detailed description

This single-arm, open-label, multiple-center clinical trial aims to study the efficacy and safety of chiauranib in the treatment of patients with advanced or unresectable soft tissue sarcoma, and to explore potential biomarkers associated with chiauranib, as well as their correlation and clinical benefits.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥ 18 years and ≤75 years.
  2. confirmed advanced or unresectable soft tissue sarcoma with failure of standard therapy or no standard therapy.
  3. At least one measurable target lesion as defined by RECIST1.1, i.e., a lesion that has radiologic evidence of disease progression, after treatment with radiotherapy or local-regional therapy
  4. (ECOG) Performance Status of 0 or 1.
  5. Laboratory criteria are as follows:

    1. Hematology: (ANC) ≥1.5×109/L, ≥75×109/L, ≥80 g/L.
    2. Biochemistry: serum creatinine \<1.5× (ULN), total ≤1.5×ULN, both (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN for patients with hepatic ).
    3. Coagulation panel: (INR) \<1.5.
  6. of at least 3 months.
  7. Willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Active central nervous system (CNS) symptoms during the screening period and/or requiring hormone therapy within 28 days before the first dose, or lesions involving the brain stem or pia mater.
  2. Imaging during the screening period showed that the tumor had invaded the periphery of the important blood vessels or the investigator judged that the tumor was likely to invade the important blood vessels and cause massive bleeding during the trial.
  3. Pleural fluid, ascites or pericardial effusion with significant symptoms or required treatment of puncture or drainage during the screening period.
  4. Current or previous history of other (other than adequately treated basal or squamous cell carcinoma of the skin or cervical carcinoma in situ) unless curative treatment has been performed and there is no evidence of recurrence or in the last 5 years
  5. Prior treatment with vascular endothelial growth factor(VEGF)/vascular endothelial growth factor receptor(VEGFR) inhibitor, like Apatinib, Anlotinib, Fruquintinib, Bevacizumab, etc., or Aurora kinase inhibitors (For patients eligible for anlotinib, only those who could not receive anlotinib for various reasons were allowed to be enrolled in this study. Patients who had previously received anlotinib were excluded from the study).
  6. Anti-tumor treatments such as radiotherapy, chemotherapy, immunotherapy and targeted therapy were used within 28 days before the first treatment.
  7. Allergic or to any component or vehicle of the test drug.
  8. Treatment with an agent/instrument within 28 days prior to first dose.
  9. Prior major surgery or trauma within 28 days prior to first dose and/or presence of any non-healing wound, fracture, or ulcer during the screening period.
  10. Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1(except alopecia) during the screening period.
  11. Uncontrolled or significant cardiovascular disease, including:

    1. (NYHA) class II or higher congestive heart failure, unstable angina pectoris, myocardial infarction occurred within 6 months before the first dose, or an arrhythmia requiring treatment during the screening period with a (LVEF) of \<50%.
    2. Primary cardiomyopathy (dilated cardiomyopathy, hypertrophic cardiomyocyte, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy).
    3. history of prolongation, or screening QTc interval >470ms for women and >450ms for men.
    4. Symptomatic coronary heart disease requiring medical treatment during the screening period.
    5. Records of concomitant use of ≥3 antihypertensive drug components within 14 days prior to the first dose, or systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg during the screening period (at rest, approximately 5 minutes apart, three consecutive measurements, averaged).
    6. Previous hypertensive crisis or hypertensive encephalopathy.
    7. Other condition investigator considered inappropriate.
  12. Chest imaging during the screening period revealed interstitial lung disease or pulmonary fibrosis or pulmonary inflammation requiring treatment, or a history of pneumonia treated with oral or intravenous within 6 months before the first dose.
  13. Significant gastrointestinal abnormalities during the screening period that were judged by the investigator to be likely to interfere with drug intake, transport, or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, post-small bowel resection, etc.), or total gastrectomy, or a history of gastrointestinal perforation and/or fistula within 6 months prior to the first dose.
  14. 24-hour urine protein quantitative examination must be performed when urine protein ≥2+ in routine urine examination during the screening period. Patients cannot be enrolled if quantitative urine protein ≥ 1g/24 h.
  15. Active bleeding within 2 months before the first dose, or taking anticoagulants during the screening period (e.g., warfarin, phenprocoumon, and allow prophylactic use of low-dose aspirin and low-molecular weight heparin), Or investigator judged that there was a high risk of bleeding during the screening period (such as esophageal and gastric fundus varices with bleeding risk, locally active ulcer lesions, positive fecal occult blood could not exclude gastrointestinal bleeding, intermittent hemoptysis, etc.).
  16. A history of deep vein thrombosis or pulmonary embolism or a thrombotic event such as a cerebrovascular accident within 6 months before the first dose (implantable venous port or catheter-derived thrombosis, investigator evaluation for enrollment).
  17. Active infections that required systemic treatment during the screening period (oral, intravenous infusion).
  18. antibody positive during the screening period.
  19. surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive with virus replication, antibody (HCV-Ab) positive with virus replication during the screening period.
  20. Any mental or cognitive impairment that may limit the understanding, execution, and adherence to the study.
  21. Drug use and long-term alcohol abuse affected the evaluation of test results.
  22. Pregnant or lactating women; Be unwilling or unable to during the treatment of this test and test the last 12 weeks after the treatment using effective methods of among women of reproductive age [women of childbearing age include: did not receive any had menstruation and successful artificial sterilization (hysterectomy and bilateral tubal ligation or bilateral oophorectomy) or menstruating]; If the partner is a woman of childbearing age, the subject is a fertile man who is not using effective contraception.
  23. Other conditions considered by the investigator to be inappropriate for trial participation, such as concomitant disease, concomitant therapy, or any laboratory abnormality, may interfere with the evaluation of efficacy and safety results.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Chiauranib capsule

    Patients take chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression

    Drug: Chiauranib

Interventions

  • 50mg, orally once daily

    Also known as: CS2164

06

What researchers measure

Primary outcomes

  1. Progression-free survival of 12 weeks(PFS12w)

    Proportion of subjects who did not have disease progression or recurrence (according to RECIST1.1) or death from any cause at week 12 after receiving medical treatment

    Time frame: 12 weeks after the first dose

Secondary outcomes

  1. Overall response rate (ORR)

    Proportion of participants who have a partial response (PR) or complete response (CR) to therapy according to RECIST 1.1

    Time frame: Up to 2 years

  2. Progression-free survival (PFS)

    From the first time of treatment until the date of first documented progression or date of death from any cause, whichever comes first

    Time frame: Up to 2 years

  3. Duration of response (DOR)

    From the first date of response until the date of first documented progression

    Time frame: Up to 2 years

  4. Disease control rate (DCR)

    Proportion of participants in partial, complete or stable disease according to RECIST 1.1.

    Time frame: Up to 2 years

  5. Overall survival (OS)

    From the first dose of treatment until the date of death from any cause

    Time frame: Up to 2 years

  6. Safety and Tolerability

    Incidence of adverse events (AEs) as assessed by CTCAE 5.0

    Time frame: Up to 28 days after the last dose

07

Study locations

1 site
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jan 2025, 28 months.

Of 227 phase 2 interventional studies under Sarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 92. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2022
First posted
Aug 11, 2022
StartActual
Aug 25, 2022
Primary completionActual
Jan 3, 2025
CompletionActual
Jan 3, 2025
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05497843
Responsible party
Sponsor
First posted
Aug 11, 2022
Start date
Aug 25, 2022
Primary completion
Jan 3, 2025
Completion
Jan 3, 2025
Last update
Apr 3, 2025

Study contacts

Xing Zhang, MD
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chiauranib

Start the discussion